Stevanato Group Wins Pharma Innovation Award For AI-ready Vision Robot Unit (VRU)

Ad - Bora Pharmaceuticals

Stevanato Group, a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, has been recognized as a winner of Pharma Manufacturing magazine’s 2021 Pharma Innovation Award for its AI-ready Vision Robot Unit (VRU) – a robotic human-like inspection unit.

Stevanato Group’s VRU inspection system is an autonomous module capable of automatically inspecting both cosmetic and particle properties without human intervention. Designed to meet emerging “smart factory” needs for high flexibility and inspection performance, the VRU can be used in a broad array of applications in the pharma development and manufacturing landscape, including small batches, high value drugs, and cell and gene therapies.

The Pharma Innovation Awards are Pharma Manufacturing’s annual celebration of new technologies and services that help advance product quality, risk reduction and manufacturing efficiency. They are presented to companies who listen to the needs of the market and their customers and have distinguished themselves as leaders in pharmaceutical equipment and technology.

“I am thrilled that the outstanding work of the Stevanato Group team has been recognized by Pharma Manufacturing magazine with a 2021 Pharma Innovation Award. As a result of our fully integrated offering, Stevanato Group engineers are able to gain unique insights into each stage of the drug development and delivery process enabling them to bring crucial automation to container inspection with this AI-ready, and now award winning, VRU.” – said Raffaele Pace, VP Operations Engineering

About Stevanato Group

Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. The Group delivers an integrated, end-to-end portfolio of products, processes and services that address customer needs across the entire drug life cycle at each of the development, clinical and commercial stages. Stevanato Group’s core capabilities in scientific research and development, its commitment to technical innovation and its engineering excellence are central to its ability to offer value added solutions to clients.